Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular-targeted photodynamic therapy using WST11 in localized prostate cancer
2008-000876-26Phase 2Active
- Sponsor
- Steba Biotech
- Start
- Mar 2008
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of padeliporfin VTP in prostate cancer (PCa), sponsored by Steba Biotech. Primary endpoint: Primary efficacy at Month 3 biopsy. Started Mar 2008; status: active.
02
Drugs
padeliporfin VTP
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-000876-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000876-26.